Opinion|Videos|October 25, 2024
Inside the Academic Approach: How Initial Consultations for Bispecific Therapy Referrals Are Handled
Panelists discuss how academic centers approach the initial consultation and evaluation process for patients referred for bispecific therapy from community practices.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- From the academic center's perspective, how do you approach the initial consultation and evaluation process for patients referred for bispecific therapy from community practices?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5